Loading company…
Rhegen develops nucleic acid drugs for cancer, infectious diseases and functional protein defects.
Established in 2019 and based in Shenzhen, China, Rhegen researches and produces nucleic acid drugs for cancer, infectious diseases and functional protein defects. Its mRNA programs include infection vaccines, cancer immunotherapy and protein substitution therapy. Its RH109 Omicron vaccine received clinical trial approval in Hong Kong, the Philippines and New Zealand.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in